SEOUL-SEMICONDUCTOR
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that it will auction its radio frequency (RF) semiconductor patent portfolio and its high power LED package patent portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005105/en/
In the first auction, Seoul Semiconductor is seeking the top bidder for 98 patent assets related to power amplifiers and gallium nitride (GaN) RF semiconductors, including 55 U.S. patents. Three of the patents are licensed to the U.S. Air Force or the U.S. Army, confirming the value of the portfolio.
This RF patent portfolio is the result of an investment of more than $100 million in R&D by Sensor Electronic Technology, Inc. (SETi), which was founded in 1999 at the Rensselaer Polytechnic Institute (RPI) in New York. SETi, which was completely acquired by Seoul Viosys in 2015, one of the affiliates of Seoul Semiconductor, was at the forefront of GaN device development for high power RF and UV LED technologies. SETi is now focused on UV LED technologies, thus its GaN RF patent portfolio is being auctioned.
GaN has a wider bandgap than silicon, which means it can sustain higher voltages than silicon, and is able to carry current through the device faster. GaN is becoming the technology of choice for mobile and satellite communications, radar, wireless charging and autonomous driving.
With 5G implementation coming soon, the GaN RF market is developing fast. The GaN RF market will grow to USD 2 billion by 2024 (Yole Développement, 2019) and the global radio frequency components market size is expected to reach USD 45 billion by 2025 (published in Market Research Report, 2019). The companies Sumitomo Chemical Co., Cree Inc., and Qorvo, Inc. hold a large share of the GaN RF market.
In the second auction, Seoul Semiconductor will auction more than 100 patents, including US, European, Chinese, Japanese, and Korean patents related to high power LED packages and adaptive lighting. High power LED packages are used in smartphone and automotive applications. Adaptive lighting is used in smartphone camera lenses and flash-lights and automotive headlights. In addition, these are some of the essential patents for high power LED chips enabling thin and small design of lenses and flash-lights to respond to market demands for diverse functions of smartphone camera.
“Seoul Semiconductor is now looking for potential buyers or licensing partners for certain of these technologies. We believe that it can be a good opportunity for startups and small-to-medium enterprises (SMEs), who have difficulty in holding key patents, to expand their business,” said Seoul Semiconductor’s founder Chung Hoon Lee and SETi’s chief executive officer Chae Hon Kim.
“Meanwhile, some large companies have negatively affected the LED industry by having unlawful access to our trade secrets by soliciting employees or preferring low-cost products that ignore intellectual property rights. As a part of our new patent management strategy, we will sell some of our patents to companies that do not compete directly, and will invest the profits from the auction to develop new technologies in the future,” added Lee and Kim.
The auction process is being handled by GoodIP , the digital licensing platform that helps tech companies and research centers identify licensing partners for their intellectual property.
About GoodIP
GoodIP helps tech companies and research centers identify licensing partners for their intellectual property through GoodIP’s digital licensing platform. GoodIP is supported by Fluxunit/Osram Ventures and the LMU Entrepreneurship Center. For more information, please visit www.goodip.io .
About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005105/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 08:00:00 CEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 07:30:00 CEST | Press release
Solid Start to the Year SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including pr
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 03:00:00 CEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 22:03:00 CEST | Press release
A Year of Broad-Based Sales Growth, Expanded Market Share and Increased Profitability, Driven by Strategic Priorities SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases.
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 21:32:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom